Cargando…

Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma

Galectins (Gals) are evolutionarily conserved proteins that bind to β-galactoside containing glycans. Abnormal expression of Gals is associated with the development, progression, and metastasis of different types of cancer. Among the 11 Gals identified in humans, the roles of Gal-1 and Gal-3 have be...

Descripción completa

Detalles Bibliográficos
Autores principales: Setayesh, Tahereh, Colquhoun, Steven D., Wan, Yu-Jui Yvonne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460053/
https://www.ncbi.nlm.nih.gov/pubmed/34567824
http://dx.doi.org/10.1016/j.livres.2020.11.001
_version_ 1784571664803037184
author Setayesh, Tahereh
Colquhoun, Steven D.
Wan, Yu-Jui Yvonne
author_facet Setayesh, Tahereh
Colquhoun, Steven D.
Wan, Yu-Jui Yvonne
author_sort Setayesh, Tahereh
collection PubMed
description Galectins (Gals) are evolutionarily conserved proteins that bind to β-galactoside containing glycans. Abnormal expression of Gals is associated with the development, progression, and metastasis of different types of cancer. Among the 11 Gals identified in humans, the roles of Gal-1 and Gal-3 have been extensively investigated in various tumors. Here, we summarize the roles of overly expressed Gal-1 and Gal-3 in the pathogenesis of hepatocellular carcinoma (HCC). The overexpression of Gal-1 and Gal-3 correlates with tumor growth, HCC cell migration and invasion, tumor aggressiveness, metastasis, and poor prognosis. A potentially promising future treatment strategy for HCC may include the combination of immunotherapy with Gal-1 inhibition. Additional research is warranted to investigate targeting Gal-1 and Gal-3 for HCC treatment.
format Online
Article
Text
id pubmed-8460053
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-84600532021-12-01 Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma Setayesh, Tahereh Colquhoun, Steven D. Wan, Yu-Jui Yvonne Liver Res Article Galectins (Gals) are evolutionarily conserved proteins that bind to β-galactoside containing glycans. Abnormal expression of Gals is associated with the development, progression, and metastasis of different types of cancer. Among the 11 Gals identified in humans, the roles of Gal-1 and Gal-3 have been extensively investigated in various tumors. Here, we summarize the roles of overly expressed Gal-1 and Gal-3 in the pathogenesis of hepatocellular carcinoma (HCC). The overexpression of Gal-1 and Gal-3 correlates with tumor growth, HCC cell migration and invasion, tumor aggressiveness, metastasis, and poor prognosis. A potentially promising future treatment strategy for HCC may include the combination of immunotherapy with Gal-1 inhibition. Additional research is warranted to investigate targeting Gal-1 and Gal-3 for HCC treatment. 2020-11-04 2020-12 /pmc/articles/PMC8460053/ /pubmed/34567824 http://dx.doi.org/10.1016/j.livres.2020.11.001 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ).
spellingShingle Article
Setayesh, Tahereh
Colquhoun, Steven D.
Wan, Yu-Jui Yvonne
Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma
title Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma
title_full Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma
title_fullStr Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma
title_full_unstemmed Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma
title_short Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma
title_sort overexpression of galectin-1 and galectin-3 in hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460053/
https://www.ncbi.nlm.nih.gov/pubmed/34567824
http://dx.doi.org/10.1016/j.livres.2020.11.001
work_keys_str_mv AT setayeshtahereh overexpressionofgalectin1andgalectin3inhepatocellularcarcinoma
AT colquhounstevend overexpressionofgalectin1andgalectin3inhepatocellularcarcinoma
AT wanyujuiyvonne overexpressionofgalectin1andgalectin3inhepatocellularcarcinoma